SITC23 Scorecard for emerging novel IO therapies

W2W4 at SITC23 - 10 emerging areas to pay attention to in IO

November 6, 2023

Gunning for new targets, new approaches

From CAR-T cells to protein degradation

September 19, 2023

Adding up the evidence

Early-stage agents in development for multiple myeloma - hit or miss?

September 7, 2023

Standing out from the crowd in AML

Encouraging new developments in the CAR-NK niche

June 27, 2023

A look at early stage trials debuting at ASCO23

What do three phase 1 and one phase 2 trials tell us about future development?

June 5, 2023

Tipping the TIGIT balance

How can we overcome immune escape in relation to TIGIT therapies?

January 9, 2023

Moving targets

Ten emerging development areas to watch out for in oncology during 2023

January 5, 2023

Emerging biotechs and novel IO concepts to watch out for

10 early stage IO biotechs to watch out for

November 30, 2022

SITC22 Preview 1 – Looking under the hood

6 abstracts to watch out for on how to overcome immune escape

October 12, 2022

Catamaran Bio sets sail in 2022

Interview with Dr Vipin Suri, CSO Catamaran Bio about the science behind their CAR-NK cell therapy.

July 27, 2022

Shoreline rides the CAR-NK wave at AACR22

First in a mini-series featuring some of the companies that presented CAR-NK cell data at AACR22

July 7, 2022

Trials and Tribulations

A look at early stage CAR-T cell therapies in development

June 5, 2022

A journey that never ends

Can NK cells help checkpoint blockade work more effectively?

April 27, 2022

An inconvenient truth

Looking beyond the hype from a broader perspective

April 18, 2022

What’s the next stop in CAR T cell therapy?

Highlights from Day 1 of CART22, part 1

February 11, 2022

What can we learn from early stage IO trials?

A look at some combination IO strategies in early clinical development to watch out for

December 9, 2021

New developments in the cell and gene therapy landscape

Novel approaches to fine tuning CAR-T cell therapies are hitting the clinic

November 17, 2021

Scores on the doors in the TIGIT niche

Update on the various runners and riders in the TIGIT niche

November 3, 2021

A review of the emerging bispecific landscape

A look at the sheer breadth and depth of bispecific approaches from a myriad of different biotechs

October 27, 2021

COAST to coast – contemplating key Stage III trials in NSCLC

A deep dive into the phase 2 COAST study, along with some expert anecdotes

September 22, 2021

The Future of Cell and Gene Therapies

13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies

April 22, 2021

Highlights and commentary on key AACR21 data presentations

13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?

April 13, 2021

5 early developments to watch out for at AACR21

What's hot in early preclinical development to watch out for?

April 5, 2021

Fifteen AACR21 On Demand Presentations To Watch

Noteworthy AACR21 on-demand presentations.

March 23, 2021

An exciting pipeline of early stage oncology agents from BMS

A critical look at the early stage BMS oncology pipeline

January 11, 2021

Future of NK Cell Therapy – Part 2

Commentary on engineered NK cells, including CAR-NK and memory-like NK cells

January 6, 2021

Future of NK Cell Therapy – Part 1

Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?

January 5, 2021

Highlights of Saturday at ASH20 Part 1

Commentary on Saturday at ASH20

December 6, 2020

What’s the skinny on a new IO target in oncology R&D?

A new emerging IO target of interest caught out attention, now what?

July 28, 2020

Putting NK cells to work

Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...

July 7, 2020

The Potential of CAR-NK Cells for Cancer Immunotherapy

Will CAR-NK cells follow CAR-T cell therapies and hit prime time?

May 13, 2020

Life, the world, and the cell therapy universe

Can innovative our ability to reinvigorate stalled CAR T cells affected by immune escape from CD19 loss or downregulation of BCMA?

January 30, 2020

JPM20 Highlights from Day 2

Highlights (and lowlights) from the second day of the JPM Healthcare conference in San Francisco

January 14, 2020

Will innate bispecifics make a difference in hematologic malignancies and solid tumours?

What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess

July 11, 2019

Key highlights on lymphomas from iCML

Round-up and analysis of key lymphoma data at iCML 2019

June 20, 2019

What to watch out for in Bispecifics at ASCO19

A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.

May 28, 2019

Pathways to success with NK cell therapy

Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?

August 28, 2018

Innate Pharma – converting science into the clinic

An in-depth look at the French biotech company Innate Pharma and where they are now two years on from our last look at their IO pipeline.

March 27, 2018

Exploring Gamida Cell with Dr Julian Adams

A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...

March 15, 2018

Targeting NK cells effectively in AML

A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies

March 14, 2018

Top 10 #ASH17 abstracts to watch out for

The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!

November 30, 2017

Targeting Natural Killer Cells in Cancer Immunotherapy

Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?

October 11, 2017

A look at Nektar Therapeutics immunotherapy pipeline

Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline

July 24, 2017

Targeting Natural Killer Cells in AML

New research shows potential of cell therapy with allogeneic memory-like natural killer NK cells in AML.

September 27, 2016

Innate Pharma at an Inflexion Point: An interview with CEO Hervé Brailly

Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company

September 20, 2016

Why target the Innate Immune system? An interview with Eric Vivier

Professor Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy and a co-founder of Innate Pharma and the Marseille Immunopôle. He is a leading researcher in the field of innate immunity.

September 19, 2016

Could a Novel Cell Therapy replace CAR T Cell Therapy?

Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy

March 1, 2016

Will anti-KIR immunotherapy make an impact in hematologic malignancies?

Immuno-oncology is a hot topic at the moment and many new targets are emerging that may be useful in combination. This post discusses Innate Pharma's anti-KIR program in hematologic malignancies.

December 12, 2013